Rapid assembly and in situ screening of bidentate inhibitors of protein tyrosine phosphatases

Organic Letters

Volumn 8, Issue 4, 2006, Pages 713-716

  Srinivasan, Rajavel ^a   Uttamchandani, Mahesh ^a   Yao, Shao Q ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ISOXAZOLE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; TRIAZOLE DERIVATIVE;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; IC 50; SYNTHESIS;

BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; INHIBITORY CONCENTRATION 50; ISOXAZOLES; MOLECULAR STRUCTURE; PROTEIN-TYROSINE-PHOSPHATASE; TRIAZOLES;

EID: 33644759169     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol052895w     Document Type: Article

References (20)

1. (1)For a review, see: (a) Arkin, M. R.; Wells, J. A. Nat. Rev. Drug Discovery 2004, 3, 301-317.
2. (b) Szczepankiewicz, B. G. et al. J. Am. Chem. Soc. 2003, 125, 4087-4096.
3. (c) Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; Wells, J. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9367-9372.
4. (d) Birk, A.; Lin, Y.-C.; Elder, J.; Wong, C.-H. Chem. Biol. 2002, 9, 891-896.
5. For a review, see: Kolb, H. C.; Sharpless, K. B. Drug Discovery Today 2003, 8, 1128-1137.
6. Wu, C.-Y. et al. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10012-10017.
7. (b) Wu, C.-Y.; Chang, C.-F.; Chen, J. S.-Y.; Wong, C.-H. Angew. Chem., Int. Ed. 2003, 42, 4661-4664.
8. (c) Best, M. D.; Birk, A.; Chapman, E.; Lee, L. V.; Cheng, W.-C; Wong, C.-H. ChemBioChem 2004, 5, 811-819.
9. (d) Lee, L. V.; Mitchell, M. L.; Huang, S.-J.; Fokin, V. V.; Sharpless, K. B.; Wong, C.-H. J. Am. Chem. Soc. 2003, 125, 9588-9589.
10. (a) Zhang, Z.-Y. Curr. Opin. Chem. Biol. 2001, 5, 416-423.
11. (b) Johnson, T. O.; Ermolieff, J.; Jirousek, M. R. Nat. Rev. Drug Discovery 2002, 1, 696-709.
12. (c) Hunter, T. Cell 2000, 100, 113-127.
13. (a) van Huijsduijnen, R. H.; Bombrun, A.; Swinnen, D. Drug Discovery Today 2002, 7, 1013-1019.
14. (b) Bialy, L.; Waldmann, H. Angew. Chem., Int. Ed. 2005, 44, 3814-3839.
15. Puius, Y. A.; Sullivan, M.; Lawrence, D. S.; Almo, S. C.; Zhang, Z.-Y. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 13420-13425.
16. Guo, X.-L.; Shen, K.; Wang, F.; Lawrence, D. S.; Zhang, Z.-Y. J. Biol. Chem. 2002, 277, 41014-41022.
17. (a) Liu, G. et al. J. Med. Chem. 2003, 46, 4232-4235.
18. (b) Liu, G. et al. J. Med. Chem. 2003, 46, 3437-3440.
19. Zhu, Q.; Huang, X.; Chen, G. Y. J.; Yao, S. Q. Tetrahedron Lett. 2004, 45, 707-710.
20. Of the 14 azides used (Scheme 2), two have chiral centers (i.e., 13 and 14). 14 was synthesized from the corresponding chiral amino acid (Supporting Information). 13 was made from its racemic starting material. No attempt was made to isolate the two enantiomers in A13. It is possible that one enantiomer may be more potent than the other.